The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
Official Title: An Open-Label, Multi-Centre, Uncontrolled, Exploratory Trial Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment After PSA-Failure in GnRH Agonist Treated Patients With Prostate Cancer
Study ID: NCT00738673
Brief Summary: This was an open-label, multi-centre, uncontrolled, exploratory trial with a duration of 12 months in two cohorts. The trial aimed to investigate Degarelix as a second-line hormonal treatment in Prostate Cancer patients who experienced PSA-Failure following gonadotropin-releasing hormone (GnRH) agonist treatment. The two cohorts differ in Testosterone levels at inclusion.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Urologische Praxis, Bautzen, , Germany
Urologische Klinik, Berlin, , Germany
Urologische Praxis, Berlin, , Germany
Urologische Praxis, Borken, , Germany
Urologische Praxis, Erkrath - Hochdal, , Germany
Urologische Praxis, Hagenow, , Germany
Martini Klinik, Hamburg, , Germany
Urologische Praxis, Husum, , Germany
Urologische Praxis, Kirchheim, , Germany
Urologische Praxis, Köln, , Germany
Urologische Praxis, Lauenburg/Elbe, , Germany
Urologische Praxis, Leipzig, , Germany
Urologische Praxis, Markkleeberg, , Germany
Urologische Klinik, Planegg, , Germany
Wissenschaftskontor Nord, Rostock, , Germany
Name: Clinical Development Support
Affiliation: Ferring Pharmaceuticals
Role: STUDY_DIRECTOR